Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3965193 in Healthy Participants and Participants With Chronic Hepatitis B
NCT05330455Phase 2Terminated
- Sponsor
- GSK
- Start
- Apr 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of GSK3965193 in hepatitis B (HBV), sponsored by GSK. Started Apr 2022; status: terminated.
02
Drugs
GSK3965193
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05330455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330455.